Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies

Cardinal Health (NYSE:CAH) announced on April 1, 2026 an expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis.

Rhea-AI Summary

Cardinal Health (NYSE:CAH) announced on April 1, 2026 an expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis. The company added a high-capacity production line to its DMF, quadrupled weekly output since late 2024, and plans further capacity increases in 2026 to support clinical and future commercial targeted alpha therapies.

The expanded supply has supported more than 15 clinical trials and aims to improve access for developers of therapies for prostate, neuroendocrine, breast, colon, melanoma, and lymphoma.

Positive

• Weekly output quadrupled since late 2024
• Added a high-capacity production line to the company's DMF
• Supported 15+ clinical trials worldwide

Negative

• Global clinical progress has been slowed by limited Ac-225 availability

Argus Apr 1 session

+0.34% close to close Open Argus

Details

News Market Reaction – CAH

In the Apr 1 session, CAH gained 0.34%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cardinal Health’s expansion of Ac-225 production, aiming to ease supply...

Analysis

This announcement highlights Cardinal Health’s expansion of Ac-225 production, aiming to ease supply constraints for targeted alpha therapies across multiple cancer types. It builds on recent growth signals, including strong Q2 FY2026 results and raised guidance. An effective S-3ASR shelf dated August 12, 2025 provides flexibility for future financing. Investors may watch how this capacity translates into additional clinical collaborations and eventual commercial manufacturing volumes.

Key Figures

Clinical trials supported: more than 15 trials Routine Ac-225 production: end of 2024 Capacity expansion timeline: 2026

Clinical trials supported

more than 15 trials

Ac-225 supplied for targeted alpha therapy studies worldwide

Routine Ac-225 production

end of 2024

Routine global Ac-225 production at scale began at end of 2024

Capacity expansion timeline

2026

Company expects to continue increasing Ac-225 production capacity in 2026

Historical Context

5 past events · Latest: Mar 24

5 events

1. Mar 24

   Earnings date notice

   24h Move

   +0.4%

   Announced timing of Q3 FY2026 earnings release and webcast details.

2. Mar 23

   Board leadership change

   24h Move

   -0.7%

   Appointed Patricia A. Hemingway Hall as new Board Chair on Gregory Kenny’s retirement.

3. Feb 24

   Biosimilars report

   24h Move

   +0.5%

   Published 2026 biosimilars report highlighting large cost savings and strong provider confidence.

4. Feb 12

   Dividend declaration

   24h Move

   +2.7%

   Board approved a quarterly dividend of $0.5107 per share payable April 15, 2026.

5. Feb 05

   Earnings beat, guidance

   24h Move

   +9.8%

   Reported strong Q2 FY2026 results and raised non-GAAP EPS outlook with buybacks.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

actinium-225 (ac-225), drug master file (dmf), cGMP-compliant, alpha-emitting radionuclide, +2 more

6 terms

actinium-225 (ac-225) medical

"Cardinal Health ... announced a significant expansion of its Actinium-225 (Ac-225) production capabilities"

Actinium-225 (Ac-225) is a rare, highly radioactive isotope used as a “warhead” in targeted cancer treatments that deliver powerful alpha particles directly to tumor cells while sparing most healthy tissue. Investors watch Ac-225 because its medical promise, very limited and complex production, regulatory approval pathway, and fragile supply chain can create large commercial opportunities or bottlenecks for companies developing radiopharmaceuticals and supporting infrastructure.

drug master file (dmf) regulatory

"The addition of a high-capacity production line to its Drug Master File (DMF)"

A drug master file (DMF) is a confidential regulatory submission that describes in detail how a drug ingredient, component, or packaging is manufactured, tested and controlled, similar to giving a regulator a private recipe and safety checklist. It matters to investors because an accepted DMF helps regulators trust product quality and can speed or enable approvals, while protecting proprietary manufacturing know‑how and reducing supply or regulatory risk for a drug program.

cGMP-compliant regulatory

"increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational"

cGMP-compliant means a manufacturer follows the current Good Manufacturing Practices required by regulators to ensure products are made safely, consistently and with documented quality controls. For investors, cGMP compliance is like a certified clean kitchen and recipe book for a company’s manufacturing: it reduces the risk of product contamination, regulatory sanctions or recalls, supports reliable supply and can be essential for getting and keeping market approvals.

alpha-emitting radionuclide medical

"Ac-225 is an alpha-emitting radionuclide that can be linked to molecules"

An alpha-emitting radionuclide is a radioactive isotope that releases alpha particles—small, highly energetic but short-range bits of radiation—often used to deliver destructive energy directly to diseased cells in targeted medical therapies. Investors care because these materials underpin a class of precision cancer treatments and carry special manufacturing, regulatory, safety and supply-chain considerations that affect development costs, clinical success odds, regulatory approval risk and commercial potential, much like a specialty ingredient that is hard to source but central to a product’s value.

theranostics medical

"at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana"

Theranostics combines a medical test with a targeted treatment so the same approach both finds disease and delivers therapy—like a guided missile that first locates a target then destroys it. For investors, it matters because pairing diagnosis and therapy can speed identification of patients who will benefit, reduce wasted treatments, create dual revenue streams (tests plus drugs), and alter regulatory and reimbursement dynamics that affect commercial potential.

targeted alpha therapies medical

"supporting the rapidly growing global demand for targeted alpha therapies"

Targeted alpha therapies are medicines that attach tiny sources of powerful, short-range radiation to molecules that seek out cancer cells, delivering a concentrated, local kill while sparing nearby healthy tissue. Investors watch them because their precision can mean stronger clinical benefits and smaller side effects than traditional treatments, which can lead to faster regulatory approval, high pricing power, and significant commercial opportunity—but also complex manufacturing and regulatory risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.

Ac-225 is an alpha-emitting radionuclide that can be linked to molecules like those designed to selectively target cancer cells. New, cutting-edge Ac-225 drug products are being developed and are becoming an increasingly promising new class of therapies for cancers including prostate, neuroendocrine, breast, colon, melanoma, and lymphoma. Despite growing demand, worldwide clinical progress has been slowed by limited availability.

Since announcing routine Ac-225 production globally at scale at the end of 2024, Cardinal Health has quadrupled its weekly output. The company expects to continue increasing production capacity in 2026, supporting the rapidly growing global demand for targeted alpha therapies.

"Expanding our Ac-225 production capacity is a critical step forward for the industry and for patients," said Shane Thrasher, Vice President of Radiopharmaceutical Manufacturing, Cardinal Health Nuclear & Precision Health Solutions. "As targeted alpha therapies progress through clinical trials, reliable access to Ac-225 remains essential. This expanded capacity strengthens our ability to meet customer needs today while preparing for significantly larger commercial volumes that may occur in the coming years."

Cardinal Health's expanded production increases access to material for research and clinical development. To date, Cardinal Health's Ac-225 has supported more than 15 clinical trials worldwide, reflecting broad engagement with pharmaceutical innovators advancing targeted alpha therapies.

"The reliable availability of Ac-225 is essential for advancing targeted alpha therapies and enabling innovation in clinical research," said Eric Bischoff, Chief of Product Development and Operations at RayzeBio (a Bristol Myers Squibb Company). "Cardinal Health's commitment to expanding production capacity helps ensure a more robust supply chain, accelerating our ability to drive progress and deliver new treatment options to patients."

Cardinal Health has supported regulatory applications for cGMP-compliant Ac-225 for customers across multiple regions worldwide.

For more information, or to secure cGMP-compliant Ac-225 supply, please visit us here. 

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom. 

Contacts
Media: Reggie Dotson, Reggie.dotson@cardinalhealth.com and (847) 887-5333
Investors: Matt Sims, Matt.Sims@cardinalhealth.com and (614) 553-3661 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-expands-actinium-225-production-capacity-to-support-growing-demand-for-novel-cancer-therapies-302729844.html

SOURCE Cardinal Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardinal Health (CAH) announce on April 1, 2026 about Ac-225 production?

Cardinal Health announced an expansion of Ac-225 production capacity at its Indianapolis CTA to support trials and future commercialization. According to Cardinal Health, it added a high-capacity production line to its DMF and has been scaling output to meet growing demand.

How much has Cardinal Health (CAH) increased Ac-225 output since late 2024?

Cardinal Health says it has quadrupled weekly Ac-225 output since the end of 2024. According to Cardinal Health, that scale-up supports ongoing clinical programs and underpins planned further capacity increases during 2026.

How will Cardinal Health's (CAH) expanded Ac-225 supply affect clinical trials?

The expansion is intended to increase access to material for research and clinical development. According to Cardinal Health, its Ac-225 has supported more than 15 clinical trials worldwide, potentially easing supply constraints for targeted alpha therapy developers.

How can biopharma companies secure cGMP-compliant Ac-225 from Cardinal Health (CAH)?

Companies can request cGMP-compliant Ac-225 supply through Cardinal Health's channels to support investigational and commercial needs. According to Cardinal Health, the expanded production line and DMF listing enable supply for clinical programs and anticipated larger commercial volumes.